Troubled Elan must find answers

SHAREHOLDERS in the troubled Elan Corporation gather in Dublin tomorrow for the annual general meeting (AGM).

Elan’s prospects were first stood on their head after the 2001 Securities and Exchange Commission investigation into the group’s accounting practices.

That investigation was preceded earlier in the year by the withdrawal of its Alzheimer’s drug after 18 patients suffered swelling of the brain.